NYSE:BHVN - Biohaven Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $103.89
  • Forecasted Upside: 7.10 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$97.00
▲ +2.01 (2.12%)

This chart shows the closing price for BHVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biohaven Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHVN

Analyst Price Target is $103.89
▲ +7.10% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Biohaven Pharmaceutical in the last 3 months. The average price target is $103.89, with a high forecast of $140.00 and a low forecast of $69.00. The average price target represents a 7.10% upside from the last price of $97.00.

This chart shows the closing price for BHVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Biohaven Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2021Cantor FitzgeraldBoost Price TargetOverweight$125.00 ➝ $140.00High
5/28/2021MizuhoBoost Price TargetBuy$90.00 ➝ $92.00Low
5/18/2021Morgan StanleyLower Price TargetEqual Weight$76.00 ➝ $69.00High
5/12/2021SVB LeerinkLower Price TargetOutperform$115.00 ➝ $105.00Medium
5/11/2021MizuhoLower Price TargetBuy$98.00 ➝ $90.00Medium
5/3/2021MizuhoLower Price TargetBuy$103.00 ➝ $98.00N/A
4/26/2021MizuhoLower Price TargetBuy$103.00 ➝ $98.00Low
4/19/2021Morgan StanleyBoost Price TargetEqual Weight$73.00 ➝ $76.00Medium
3/11/2021UBS GroupInitiated CoverageBuy$108.00High
3/2/2021MizuhoBoost Price TargetBuy$93.00 ➝ $103.00High
3/1/2021Piper SandlerBoost Price TargetOverweight$90.00 ➝ $110.00Low
2/5/2021William BlairReiterated RatingBuyMedium
1/19/2021MizuhoLower Price Target$100.00 ➝ $93.00High
1/19/2021Canaccord GenuityLower Price TargetBuy$110.00 ➝ $101.00High
1/19/2021HC WainwrightLower Price TargetBuy$121.00 ➝ $111.00High
12/29/2020Cantor FitzgeraldBoost Price TargetOverweight$109.00 ➝ $115.00N/A
12/16/2020Morgan StanleyBoost Price TargetEqual Weight$63.00 ➝ $73.00Medium
12/15/2020HC WainwrightInitiated CoverageBuy$121.00Medium
12/7/2020SVB LeerinkBoost Price TargetOutperform$85.00 ➝ $120.00Medium
11/16/2020Canaccord GenuityBoost Price TargetBuy$80.00 ➝ $110.00Low
11/13/2020MizuhoBoost Price TargetBuy$82.00 ➝ $100.00Low
10/13/2020WedbushBoost Price TargetOutperform$96.00 ➝ $99.00Low
10/13/2020Morgan StanleyBoost Price TargetEqual Weight$57.00 ➝ $63.00Low
8/24/2020Morgan StanleyLower Price TargetEqual Weight$60.00 ➝ $57.00High
8/10/2020William BlairReiterated RatingBuyHigh
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$50.00 ➝ $60.00Low
6/26/2020MizuhoInitiated CoverageBuy$85.00Low
6/23/2020Cantor FitzgeraldBoost Price TargetOverweight$82.00 ➝ $109.00Low
6/18/2020WedbushBoost Price TargetOutperform$74.00 ➝ $94.00Low
6/15/2020CowenBoost Price TargetOutperform$60.00 ➝ $80.00High
6/9/2020MizuhoReiterated RatingBuy$53.00 ➝ $85.00High
5/20/2020MizuhoReiterated RatingBuy$53.00High
5/11/2020Cantor FitzgeraldBoost Price TargetOverweight$75.00 ➝ $82.00Low
5/11/2020Morgan StanleyBoost Price TargetEqual Weight$46.00 ➝ $50.00High
5/8/2020OppenheimerReiterated RatingHold$41.00Low
4/22/2020Canaccord GenuityReiterated RatingBuyHigh
4/17/2020CowenInitiated CoverageOutperform$45.00High
4/15/2020Morgan StanleyLower Price TargetEqual Weight$49.00 ➝ $46.00Medium
3/31/2020OppenheimerLower Price TargetMarket Perform$48.00 ➝ $37.00Low
3/13/2020WedbushBoost Price TargetOutperform$73.00 ➝ $78.00High
2/23/2020MizuhoReiterated RatingBuy$58.00High
2/11/2020Canaccord GenuityReiterated RatingBuy$80.00Medium
2/10/2020The Goldman Sachs GroupLower Price TargetBuy$89.00 ➝ $76.00Medium
2/10/2020OppenheimerDowngradeOutperform ➝ Market Perform$67.00 ➝ $51.00High
2/5/2020MizuhoInitiated CoverageBuy$62.00Low
1/29/2020WedbushReiterated RatingBuy$75.00High
12/23/2019Piper Jaffray CompaniesReiterated RatingBuy$100.00Medium
12/17/2019Piper Jaffray CompaniesReiterated RatingBuy$100.00Medium
12/12/2019WedbushInitiated CoverageOutperform$75.00Low
12/10/2019William BlairReiterated RatingBuyLow
12/6/2019SVB LeerinkBoost Price TargetPositive ➝ Outperform$62.00 ➝ $64.00Medium
11/27/2019WedbushInitiated CoverageOutperform$75.00N/A
11/21/2019WedbushInitiated CoverageOutperform$75.00High
10/28/2019Cantor FitzgeraldBoost Price TargetOverweight$87.00 ➝ $92.00High
10/9/2019OppenheimerSet Price TargetBuy$67.00N/A
9/17/2019William BlairReiterated RatingBuyLow
9/4/2019Cantor FitzgeraldSet Price TargetBuy$87.00Low
9/4/2019The Goldman Sachs GroupSet Price TargetBuy$89.00Low
8/26/2019Canaccord GenuitySet Price TargetBuy$80.00Low
8/9/2019Morgan StanleySet Price TargetHold$50.00High
7/22/2019Morgan StanleyLower Price TargetEqual Weight$55.00 ➝ $51.00High
7/15/2019Morgan StanleySet Price TargetHold$55.00Low
6/25/2019Canaccord GenuityReiterated RatingBuy ➝ Buy$89.00 ➝ $84.00Low
6/19/2019OppenheimerSet Price TargetBuy$68.00Medium
5/31/2019BarclaysReiterated RatingHold$55.00Low
5/14/2019Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $57.00High
5/8/2019Needham & Company LLCBoost Price TargetBuy$70.00High
5/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$75.00 ➝ $100.00High
5/6/2019The Goldman Sachs GroupInitiated CoverageBuy$92.00 ➝ $92.00High
4/23/2019SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $67.00Medium
4/15/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$54.00 ➝ $70.00Low
4/15/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$46.00 ➝ $89.00Medium
4/9/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$49.13Low
3/19/2019BarclaysReiterated RatingHold$52.00Medium
3/19/2019OppenheimerReiterated RatingBuyLow
3/18/2019Piper Jaffray CompaniesSet Price TargetBuy$75.00Low
3/6/2019Cantor FitzgeraldBoost Price TargetOverweight$82.00High
3/4/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $56.00Medium
2/8/2019Cantor FitzgeraldReiterated RatingBuy$75.00High
12/28/2018OppenheimerLower Price TargetOutperform$63.00 ➝ $54.00Low
12/10/2018Cantor FitzgeraldSet Price TargetBuy$65.00Low
12/10/2018Piper Jaffray CompaniesSet Price TargetBuy$65.00Medium
12/10/2018OppenheimerSet Price TargetBuy$63.00Low
12/3/2018OppenheimerSet Price TargetBuy$63.00High
12/3/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
11/29/2018Piper Jaffray CompaniesReiterated RatingBuy$65.00High
11/27/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Buy$55.00High
11/15/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Buy$57.00 ➝ $55.00High
11/15/2018William BlairReiterated RatingOutperformHigh
11/14/2018Piper Jaffray CompaniesSet Price TargetBuy$65.00High
11/12/2018SVB LeerinkInitiated CoverageOutperform$50.00Low
11/12/2018OppenheimerInitiated CoverageBuy$63.00Low
10/24/2018Piper Jaffray CompaniesReiterated RatingBuy$65.00High
10/18/2018Cantor FitzgeraldSet Price TargetBuy$57.00Low
10/12/2018Cantor FitzgeraldReiterated RatingBuy$57.00High
10/11/2018Morgan StanleyReiterated RatingBuy$47.00High
10/1/2018Cantor FitzgeraldReiterated RatingBuy$57.00Low
9/12/2018Cantor FitzgeraldSet Price TargetBuy$57.00High
9/12/2018Piper Jaffray CompaniesSet Price TargetBuy$65.00High
9/11/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$44.00 ➝ $45.00High
8/23/2018Cantor FitzgeraldInitiated CoverageOverweight$55.00Medium
8/17/2018Canaccord GenuityReiterated RatingBuy$43.00Low
8/17/2018Needham & Company LLCReiterated RatingBuy$48.00Low
8/16/2018Piper Jaffray CompaniesSet Price TargetBuy$48.00High
7/13/2018Morgan StanleyBoost Price TargetOverweight$39.00 ➝ $44.00High
7/12/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $50.00Medium
7/2/2018Needham & Company LLCBoost Price TargetBuy$36.00 ➝ $48.00Medium
7/1/2018Canaccord GenuitySet Price TargetBuy$40.00Medium
6/28/2018Cantor FitzgeraldSet Price TargetBuy$42.00Low
6/19/2018BarclaysBoost Price TargetEqual Weight$40.00Low
6/14/2018Cantor FitzgeraldReiterated RatingOverweightLow
6/11/2018Canaccord GenuityReiterated RatingBuy$40.00High
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$42.00High
6/8/2018Piper Jaffray CompaniesSet Price TargetBuy$48.00High
5/22/2018Canaccord GenuityReiterated RatingBuy$35.00Low
5/16/2018Canaccord GenuitySet Price TargetBuy$35.00High
5/16/2018Needham & Company LLCReiterated RatingBuy$36.00Low
4/27/2018Canaccord GenuitySet Price TargetBuy$34.00Low
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$30.00 ➝ $25.00Medium
3/26/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
3/26/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$39.00 ➝ $34.00High
3/7/2018Canaccord GenuitySet Price TargetBuy$39.00Low
2/22/2018Needham & Company LLCReiterated RatingBuyHigh
2/22/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$30.00 ➝ $39.00Medium
12/15/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$30.00Medium
12/11/2017Piper Jaffray CompaniesSet Price TargetBuy$48.00Medium
11/15/2017Needham & Company LLCReiterated RatingBuy$36.00N/A
10/3/2017William BlairReiterated RatingOutperformLow
10/3/2017Morgan StanleyReiterated RatingOverweight ➝ Overweight$47.00 ➝ $38.00High
10/3/2017Needham & Company LLCLower Price TargetBuy$43.00 ➝ $36.00High
9/25/2017Morgan StanleyBoost Price TargetOverweight$28.00 ➝ $47.00High
9/13/2017Needham & Company LLCReiterated RatingBuy$30.00 ➝ $43.00Low
9/12/2017Piper Jaffray CompaniesReiterated RatingBuy$54.00Low
5/31/2017Morgan StanleyInitiated CoverageOverweight ➝ OverweightMedium
5/30/2017William BlairInitiated CoverageOutperform$46.00High
5/30/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$30.00High
5/30/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$21.00High
5/30/2017BarclaysInitiated CoverageOverweight ➝ Overweight$30.00High
(Data available from 6/22/2016 forward)
Biohaven Pharmaceutical logo
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $97.00
Low: $93.21
High: $98.63

50 Day Range

MA: $80.71
Low: $66.05
High: $105.02

52 Week Range

Now: $97.00
Low: $57.66
High: $106.57

Volume

941,580 shs

Average Volume

654,037 shs

Market Capitalization

$6.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Biohaven Pharmaceutical?

The following Wall Street sell-side analysts have issued stock ratings on Biohaven Pharmaceutical in the last twelve months: Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, Mizuho, Morgan Stanley, Piper Sandler, SVB Leerink LLC, UBS Group AG, Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BHVN.

What is the current price target for Biohaven Pharmaceutical?

9 Wall Street analysts have set twelve-month price targets for Biohaven Pharmaceutical in the last year. Their average twelve-month price target is $103.89, suggesting a possible upside of 7.1%. Cantor Fitzgerald has the highest price target set, predicting BHVN will reach $140.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $69.00 for Biohaven Pharmaceutical in the next year.
View the latest price targets for BHVN.

What is the current consensus analyst rating for Biohaven Pharmaceutical?

Biohaven Pharmaceutical currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHVN will outperform the market and that investors should add to their positions of Biohaven Pharmaceutical.
View the latest ratings for BHVN.

What other companies compete with Biohaven Pharmaceutical?

How do I contact Biohaven Pharmaceutical's investor relations team?

Biohaven Pharmaceutical's physical mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company's listed phone number is 203-404-0410. The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.